Atlas Trials

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Clinical trial NCT05210803 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT05210803
Sponsor
AbbVie
Status
ENROLLING_BY_INVITATION
Phase
Phase 2
Study type
INTERVENTIONAL
Neovascular Age-Related Macular Degeneration (nAMD)
Start date
2021-12-20
Primary completion
2031-07-01
Enrollment
116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.